BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30148717)

  • 1. Molecular classification of adult gliomas: recent advances and future perspectives.
    Barritault M; Meyronet D; Ducray F
    Curr Opin Oncol; 2018 Nov; 30(6):375-382. PubMed ID: 30148717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic gliomas in adults: an update.
    Izquierdo C; Joubert B; Ducray F
    Curr Opin Oncol; 2017 Nov; 29(6):434-442. PubMed ID: 28901965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
    Weller M; Reifenberger G
    Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Classification of Diffuse Gliomas.
    Kalidindi N; Or R; Babak S; Mason W
    Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
    Sonoda Y
    Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of gliomas: from morphology to molecules.
    Ferris SP; Hofmann JW; Solomon DA; Perry A
    Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L; Di Stefano AL; Ducray F
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Classification of gliomas. Current progress and perspectives].
    Capper D; Reifenberger G
    Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
    Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
    Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
    Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
    J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular classification of gliomas.
    Masui K; Mischel PS; Reifenberger G
    Handb Clin Neurol; 2016; 134():97-120. PubMed ID: 26948350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.